Roche completes sale to CMO Delpharm of Italian formulation facility

Roche has completed its deal to sell a plant in Italy to Delpharm.

Pharma giant Roche has completed the sale of its solid and liquid formulation facility in Segrate, Italy, to CMO Delpharm, which reached a deal to supply the Swiss pharma giant with product produced at the plant.

The divestment to Delpharm was completed last week, a spokeswoman told FiercePharmaManufacturing. Financial terms were not disclosed.

“Delpharm acquires the site as it is, taking over its people and assets,” Roche spokeswoman Anja von Treskow said in an email. “The agreement between Roche and Delpharm includes a multiyear manufacturing contract, where it is intended that Delpharm will continue to support solid and liquid forms production for Roche in the future.”

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The Segrate facility is the second in Italy for Delpharm, which has 12 plants overall. 

Late last year, Roche announced it would close or sell four plants, including Segrate, and lay off 1,200 people as part of its plan to transition to new technology for manufacturing small-molecule drugs. It plans to build a late-stage technical development and launch facility in Switzerland for targeted, high-potency drugs.

As part of the agreement with Roche, Delpharm will keep on all the plant’s employees at the Segrate plant. 


Suggested Articles

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job.